Bioactive lipid mediators originating from the cleavage of structural lipid components of cellular membranes represent one of the most potent classes of endogenous inflammatory mediators. Eicosanoids, which are a large family of compounds generated from arachidonic acid, are a paradigmatic example of this class of lipid mediators. Arachidonic acid is an essential ω-6-polyunsaturated fatty acid (PUFA) primarily found esterified in the 2-acyl position of phospholipids in all mammalian outer-and intracellular membranes. Upon activation of phospholipase A 2 , arachidonic acid is released from membrane phospholipids, and its free acid becomes available as a substrate for the intracellular biosynthesis of eicosanoids through two major enzymatic routes: the cyclooxygenase (COX) and lipoxygenase (LO) pathways. The COX pathway results in the formation of prostaglandins (PGs) and thromboxane A 2 , which are known for their powerful physiological properties and PGs specially, for their critical role in the inflammatory response. On the other hand, the LO pathway comprises three major LOs: 5-, 12-, and 15-LO, with 5-LO, which converts arachidonic acid into 5(S)-hydroxyeicosatetraenoic acid and leukotrienes (LTs), a consolidated pharmacological target in inflammation.
process, and not only stop PMN and eosinophil functions, but also pave the way for monocyte migration and their differentiation to phagocytosing macrophages, which remove dead cells and then terminate the inflammatory response. A concept that is currently of interest is that loss or deterioration of tissue function during chronic inflammation is the result of an inappropriate inflammatory response that remains uncontrolled because of the lack of the intrinsic capacity of the tissue for complete resolution. Therefore, the modulation of these "stop signals" that promote the timely resolution of inflammation is emerging as a strategy to maintain inflammation self-limiting and to prevent tissue injury and disease.
This special issue on "Resolution of Acute Inflammation and the Role of Lipid Mediators" is devoted to describe the current status, characteristics, and progress in this class of "stop signals", especially on the role of lipoxins and the recently described ω-3-PUFA-derived lipid mediators, resolvins and protectins, in the resolution of inflammation. The paper by Mario Romano [1] reviews the available literature on lipoxins and aspirin-triggered lipoxins, which are eicosanoids emerging as pivotal break signals of inflammation and promoters of resolution. Their biosynthetic pathways, bioactions, and involvement in human disease are discussed as well as their potential use as a new class of anti-inflammatory drugs. The contribution by Gerard Bannenberg [2] discusses different aspects of the therapeutic applicability of endogenous anti-inflammatory and proresolving lipid mediators, and indicates that the development of innovative pharmacotherapy based on these endogenous compounds presents novel prospects for the treatment of inflammatory diseases. In their review, Arita and collaborators [3] focus on the biosynthesis, chemical structure, and action of resolvins in immune systems and describe the identification of these novel lipid mediators derived from ω-3-PUFA as potent immune regulators with anti-inflammatory and/or proresolving properties. The contribution by Carlo and Levy [4] describes the resolution programs that prevent bystander lung injury from excessive inflammation. These authors review rapidly emerging information on cellular and molecular mechanisms for lipoxins, resolvins, and protectins as potent anti-inflammatory and proresolving actions in the airway. González-Périz and Clària [5] review the switch to the formation of anti-inflammatory and proresolving ω-3-PUFA-derived lipid autacoids, such as resolvins and protectins, during the resolution of adipose tissue inflammation. These authors recognize the role of the endogenous compounds in stopping the state of chronic "low-grade" inflammation in adipose tissue, which predisposes to obesity-related comorbidities, such as insulin resistance and nonalcoholic fatty liver disease. The contribution of Gronert and Liclian [6] summarizes the current state of the field regarding the protective endogenous lipid circuits that have emerged as key components of endogenous pathways that preserve ocular function and limit the sequelae of ocular injury. Furthermore, the review by Börgeson and Godson [7] focuses on the evidence for molecular circuits of resolution mediated by lipid mediators, such as lipoxins, resolvins, and protectins, in renal disease. Finally, Díez-Dacal and Pérez-Sala [8] elaborate on electrophilic prostanoids like the cyclopentenone PGs acting through signaling mechanisms dependent on cysteine modification. These lipid mediators unveil a critical interplay between the cellular redox status, the electrophilic/antioxidant response, and the resolution of inflammation, which is already yielding novel anti-inflammatory targets.
